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1.352) and 0.385(0.248; 0.596) respectively for OS and PFS. Survival extrapolation pro-
vided estimates of 8 month of additional OS gain for Lenvatinib vs. sorafenib, with 
MAIC extrapolation showing largest gain and a good model fit. ConClusions: This 
analysis demonstrated that in absence of head-to-head trials, MAIC is an important 
methodology to adjust for population and trial differences, especially in orphan dis-
eases where limited data are available. MAIC can increase reliability of comparative-
effectiveness data and support payers decision making.
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objeCtives: In the COU-AA-301 trial, abiraterone acetate with low-dose prednisone 
(AA) was found to extend survival in metastatic castrate resistant prostate cancer 
(mCRPC) patients progressing after docetaxel chemotherapy compared to placebo 
with low-dose prednisone. This study aimed to evaluate AA treatment duration in 
routine clinical practice in mCRPC patients in four European countries. Treatment 
sequencing and survival data were assessed to place the treatment duration into 
context. Results for France and the Netherlands are reported. Methods: The study 
was designed as a retrospective chart review. Patients were identified through treat-
ing oncologists and urologists. Eligible mCRPC patients were aged ≥ 18 years, pre-
viously treated with docetaxel and naïve to prior AA treatment. Baseline patient 
characteristics were described using summary statistics. Kaplan-Meier survival 
analyses were performed for AA treatment duration, overall survival (OS) and time 
to prostate-specific antigen (PSA) progression endpoints. Results: A total of 68 
physicians (France and the Netherlands) reported data on 269 mCRPC patients 
treated with AA. Median PSA (ng/mL) of patients from France and the Netherlands at 
baseline were 56.0 (interquartile range [IQR]: 28.0-120.0) and 174.5 (IQR: 69.5-371.5), 
respectively. The median time (months) between mCRPC diagnosis and AA initiation 
was 12.6 (IQR: 7.0-27.2) in France and 18.3 (IQR: 9.6-30.2) in the Netherlands. Median 
(months) AA treatment duration, median OS and median time to PSA progression in 
France was 11.3 (95% confidence interval [95%CI]: 8.3-13.7), 21.6 (95%CI: 14.5-.) and 
13.8 (95%CI: 11.0-14.7), respectively. In the Netherlands, it was 4.9 (95%CI: 3.4-6.4), 
11.0 (95%CI: 7.3-13.0) and 4.9 (95%CI: 3.0-7.3), respectively. ConClusions: Here we 
describe the real-world treatment of mCRPC patients receiving AA in the post-chem-
otherapy setting in two EU countries. This study suggests that initiating AA earlier 
in the post chemotherapy mCRPC setting may result in better health outcomes.
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objeCtives: To compare adherence, persistence and switching pattern of tyrosin 
kinase inhibitor (TKIs) imatinib, dasatinib, and nilotinib in patients with newly 
diagnosed Ph+ CML from Korean national health insurance (NHI) claims data-
base. Methods: Adults newly diagnosed Ph+ CML (ICD-10: C92.1) patients with 
imatinib, dasatinib, or nilotininb prescription claims between January 1, 2012 and 
December 31, 2012 were identified form the NHI claims database. The first day of TKI 
treatment following Ph+ CML diagnosis was defined as the index date. Adherence 
was measured using Medication possession ratio (MPR) (Poor MPR: < 70%, Good 
MPR ≥ 90%). Duration of TKI use was determined based on a gap in TKI of ≥ 180 
consecutive days after TKI initiation or switch to another TKI within the 180-day 
window. Results: A total of 304 patients were identified. The 184imatinib patients, 
the 70 dasatinib patients, and 51 nilotinib patients were similar in mean age, gender 
and comorbidity at baseline. Based on the 180-day gap definition of discontinua-
tion, it was not significantly different. Mean MPR (imatinib 89.1%, dasatinib 91.2%, 
nilotinib 91.6%, p-value= 0.4763) and persistency (imatinib 78.7%, dasatinib 88.5%, 
nilotinib 95.3%, p-value= 0.411) was also not significantly different among three 
groups. However, switch to second TKI therapy from index TKI in imatinib group was 
significantly higher than dasatinib and nilotinib (p< 0.001). Patients with Good MPR 
showed higher survival rate (p= 0.0039) and patients who do not switch to other TKIs 
showed higher survival rate (p= 0.0040). ConClusions: In a retrospective assess-
ment of patients with CP-CML treated with imatinib, dasatinib and nilotinib, using 
NHI claims data have shown that imatinib was used more frequently than other 
TKI in the first-line setting. Furthermore adherence and discontinuation was not 
different among patients receiving TKI. It would be needed to follow up how treat-
ment decisions for patients with CML are changed over time in routine clinical 
practice in Korea
PCN36
NeW Drugs iN ADvANCeD melANomA: DisPArities iN requiremeNts for 
Post-lAuNCh reAl-WorD eviDeNCe iN euroPe
Langham J, Floyd D
PHMR Ltd, London, UK
objeCtives: To determine country-specific requirements for real-world evidence 
(RWE) in Europe to support ongoing market access for new drugs to treat advanced 
melanoma. General perception suggests that RWE is crucial for demonstrating 
long-term value of innovative products. However, it is unclear how these percep-
tions correlate with absolute requirements of reimbursement agencies. Methods: 
We reviewed published health technology assessments (HTAs) and reimburse-
ment agency web sites for feasible data sources for melanoma RWE generation 
and guidance on collecting RWE in Europe. We also performed a pragmatic review 
of peer-reviewed literature to identify examples of published RWE in melanoma, 
and sought views of market access specialists from a global pharmaceutical com-
PCN31
eroltiNib Plus gemCitAbiNe ComPAreD With gemCitAbiNe 
moNotherAPy iN PAtieNts With PANCreAtiC CANCer: A reAl-WorlD 
ANAlysis of KoreAN NAtioNA-WiDe DAtAbAse
Shin S1, Park C2, Kwon H1, Suh J1, Cho S1, Shin M1
1National Evidence based Health-care Collaborating Agency, Seoul, South Korea, 2National 
Evidence-based Health-care Collaborating Agency, Seoul, South Korea
objeCtives: This national population-based retrospective study aimed to evaluate 
the relative effectiveness of adding erlotinib to gemcitabine with pancreatic cancer 
patients compared to gemcitabine in real clinical practice. Methods: Patients was 
identified retrospectively using Korean National Health Insurance claims database 
who pancreatic cancer (ICD-10: C25) who initiated chemotherapy with gemcitabine 
or erlotinib between January 1, 2007 and December 31, 2012. To be included in the 
study population, patients were required to have a history of intervention for histo-
logic or cytologic diagnosis within one year before chemotherapy. For homogeneity, 
patients were excluded if they have diagnosed with other cancers where gemcit-
abine is indicated or prior radiotherapy or surgical treatment. Results: A total 
of 4,267 patients were included. Overall survival was not significantly longer in 
patients treated with gemcitabine/erlotinib (median 6.77 months for gemcitabine/
erlotinib vs. 6.68 months for gemcitabine, p= 0.0977). One-year survival rate was 
also not significantly different (27.0% vs. 27.3%; p= 0.5988). Based on this relative 
effectiveness, incremental cost per life year gained over gemcitabine was estimated 
at USD 70,843.64 for gemcitabine plus erlotinib. ConClusions: Combination of 
gemcitabine/erlotinib of advanced pancreatic cancer is not more effective than 
gemcitabine monotherapy in a real-world setting. It does not provide reasonable 
cost-effectiveness over gemcitabine alone, and reimbursement strategies for pan-
creatic cancer in Korea could be reconsidered.
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objeCtives: To assess relative efficacy and safety of second-line treatments in 
chronic myeloid leukaemia (CML), a systematic review (SR) and network meta-
analysis (NMA) feasibility study were conducted. Methods: A SR was conducted 
in January 2015 (Embase, MEDLINE, Cochrane Library, Clintrials.gov and conferences) 
to identify comparative trials evaluating treatment outcomes in patients with CML 
previously treated with tyrosine kinase inhibitors. Eligible studies were examined 
to assess NMA feasibility. Results: Twenty-three publications relating to six ran-
domised controlled trials (RCTs) on second-line treatment met the eligibility criteria. 
Included studies compared either nilotinib (n= 3) or dasatinib (n= 1) with imatinib, or 
studied dasatinib at alternative doses (n= 2). No comparative bosutinib or ponatinib 
studies were identified. Efficacy outcomes were reported using various definitions 
and different time points. Compared with nilotinib, significantly fewer imatinib 
treated patients with complete cytogenetic response (CCyR) at baseline, achieved 
complete molecular response (CMR) (23% vs 11%, p= 0.02) by 12 and confirmed CMR 
(22.1% vs 8.7%, p= 0.0087) by 24 months and in patients without major molecular 
response (MMR) at baseline, MMR by 12 (75% vs 36%, p= 0.006) and 24 (83.3% vs 
53.6%, p= 0.0342) months. Compared with imatinib, significantly more dasatinib 
patients achieved CCyR (16% vs 40%, p= 0.004; 18% vs 44%, p= 0.0025), MMR (4% vs 
16%, p= 0.038; 12% vs 29%, p= 0.028) and complete haematologic response (82% vs 
93%, p= 0.034; 82% vs 93%, p= 0.0341) at 15 and 24 months, respectively. Interpretation 
of safety data was inconclusive due to its limited availability and treatment expo-
sure differences. Even considering prospective non-RCTs, NMA was not feasible 
due to missing network links, significant differences between trial populations, 
and varying follow-up times. ConClusions: Review of all published comparative 
studies on second-line treatment of CML confirms that, based on direct efficacy 
results, dasatinib and nilotinib are the second line agents of choice. NMA comparing 
nilotinib and dasatinib was not feasible.
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objeCtives: Indirect treatment comparisons (ITCs) are important when evaluat-
ing comparative-effectiveness in absence of head-to-head clinical trials. Classic 
ITCs can lead to biased results due to differences in patient populations and trial 
designs. These differences can be corrected for by using matching-adjusted-ITC 
(MAIC) technique. Furthermore, extrapolation of survival data beyond clinical trial 
results may be required for economic evaluations. The objective of this research 
was to compare lenvatinib and sorafenib in patients with RAI-Refractory DTC using 
MAIC and survival extrapolation techniques. This analysis is an update to the MAIC 
published previously using a later data cut-off date for both drugs. Methods: Mean 
overall-survival (OS) and progression-free survival (PFS) outcomes were estimated 
by weighting patient-level data based on baseline characteristics from individual 
phase III trials using logistic regression. Classic ITC was performed before and 
after adjustment. Cross-over correction was also applied. Extrapolation of OS and 
PFS was performed using proportional hazard, accelerated time failure, individual 
parametric models and piecewise models. Results were presented as hazard-ratios 
(HR) with confidence-intervals (CI). Results: Unadjusted ITCs for Lenvatinib vs. 
placebo were 0.545(0.350; 0.830) for OS and 0.213(0.158; 0.288) for PFS. MAIC pro-
vided statistically significant estimates of 0.505(0.300; 0.820) for OS and 0.227(0.159; 
0.326) for PFS vs. placebo. Unadjusted ITCs vs. sorafenib were 0.790(0.453; 1.379) and 
0.361(0.244; 0.534) respectively for OS and PFS; while MAIC results were 0.732(0.396; 
